Abstract
Islet transplantation can relieve glucose instability and problems with hypoglycemia while the graft is functioning. However, the long-term results of islet transplantation pointed to the need for progress improving islet graft function. We started the phase II clinical trial with type 1 diabetes patients for islet transplantation using both brain-dead donors and DCD to evaluate ATG induction and TNF inhibition protocol. Primary endpoints are the proportion of subjects with HbA1c<7.4% and who are free of severe hypoglycemic events one years after the first islet cell infusion. This trial would play a critical role in establishing islet transplantation in Japan.
